TVGH (N = 69)a | TCGA (N = 299)a | |||||||
---|---|---|---|---|---|---|---|---|
Characteristics | Univariate analysis | Multivariate analysisc | Univariate analysis | Multivariate analysisc | ||||
HR (95 % CI)b | p-valueb | HR (95 % CI)b | p-valueb | HR (95 % CI)b | p-valueb | HR (95 % CI)b | p-valueb | |
Eight-probe panel | ||||||||
Risk < Median | 1.00 | 1.00 | 1.00 | 1.00 | ||||
Risk > Median | 2.37 (1.24–4.53) | 0.009 | 2.03 (1.04–3.98) | 0.039 | 1.66 (1.03–2.66) | 0.038 | 1.57 (0.96–2.57) | 0.073 |
Gender | ||||||||
Male | 1.00 | - | 1.00 | - | ||||
Female | 1.43 (0.71–2.88) | 0.321 | - | - | 0.78 (0.49–1.26) | 0.315 | - | - |
Stage | ||||||||
Stage IA | 1.00 | 1.00 | 1.00 | 1.00 | ||||
Stage IB | 2.13 (0.73–6.16) | 0.164 | 2.01 (0.69–5.86) | 0.199 | 1.15 (0.63–2.11) | 0.642 | 1.17 (0.63–2.16) | 0.616 |
Stage IIA | 8.76 (2.10–36.53) | 0.003 | 5.79 (0.72–46.58) | 0.099 | 2.17 (0.98–4.81) | 0.057 | 0.85 (0.21–3.38) | 0.817 |
Stage IIB | 6.11 (1.81–20.64) | 0.003 | 3.65 (0.70–18.92) | 0.124 | 2.04 (1.07–3.91) | 0.031 | 0.91 (0.26–3.15) | 0.885 |
T stage | ||||||||
Stage 1–2 | 1.00 | - | 1.00 | - | ||||
Stage 3–4 | 2.22 (0.53–9.28) | 0.277 | - | - | 0.62 (0.15–2.53) | 0.502 | - | - |
T stage | ||||||||
Stage 1 | 1.00 | - | 1.00 | - | ||||
Stage 2 | 1.23 (0.56–2.68) | 0.613 | - | 1.28 (0.77–2.12) | 0.338 | - | ||
Stage 3 | 2.59 (0.54–12.32) | 0.232 | - | - | 0.72 (0.17–3.07) | 0.657 | - | - |
N stage | ||||||||
N0 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
≥ N1 | 3.95 (1.88–8.30) | 0.001 | 1.54 (0.35–6.91) | 0.571 | 2.27 (1.38–3.73) | 0.001 | 2.51 (0.74–8.43) | 0.138 |
Chemotherapy | ||||||||
No | 1.00 | - | ||||||
Yes | 1.84 (0.92–3.69) | 0.084 | - | - | ||||
TKI treatment | ||||||||
No | 1.00 | - | ||||||
Yes | 2.03 (0.79–5.26) | 0.144 | - | - | ||||
Surgery | ||||||||
Lobectomy | 1.00 | - | ||||||
Wedge resection | 1.35 (0.53–3.45) | 0.536 | - | |||||
Segmentectomy | 2.98 (0.40–22.31) | 0.288 | - | - |